STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer
MADRID — A type of targeted chemotherapy developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer, a common gynecological cancer, according to randomized Phase 3 study results…
ImpactNotable 49/100
Why it mattersnimble: medium (p 0.58)
RegionsGlobal
Published22 h ago (Mon, 26 Oct 2026 15:30:00 GMT)
RetrievedMon, 26 Oct 2026 16:00:32 GMT via rss
ClassifiedMon, 26 Oct 2026 16:07:28 GMT by nimble
AuthorAdam Feuerstein